5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: Modulation by chronic paroxetine treatment

Journal of Neurochemistry

Volumn 115, Issue 2, 2010, Pages 438-449

  Mongeau, Raymond ^a,b   Martin, Cédric B P ^a,b   Chevarin, Caroline ^a,b   Maldonado, Rafael ^c   Hamon, Michel ^a,b   Robledo, Patricia ^c,d   Lanfumey, Laurence ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d Barcelona Biomedical Research Park   (Spain)

Author keywords

Antidepressant drugs; Anxiety; Mice; Paroxetine; Serotonin; Social interaction test

Indexed keywords

PAROXETINE; SEROTONIN 2C RECEPTOR; (3 CHLOROPHENYL)PIPERAZINE; 1-(3-CHLOROPHENYL)PIPERAZINE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ETHYLAMINE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; EXTRACELLULAR SPACE; FRONTAL CORTEX; IMMOBILIZATION STRESS; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SEROTONIN BRAIN LEVEL; SEROTONIN METABOLISM; SEROTONIN RELEASE; SEROTONIN UPTAKE; SEROTONINERGIC TRANSMISSION; SOCIAL INTERACTION; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; DRUG EFFECT; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; HUMAN RELATION; MENTAL STRESS; METABOLISM; MOTOR ACTIVITY; PATHOLOGY;

MUS;

AMPHETAMINES; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; BRAIN; ETHYLAMINES; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; INDOLES; INTERPERSONAL RELATIONS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PAROXETINE; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; STRESS, PSYCHOLOGICAL;

EID: 78649683879     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06932.x     Document Type: Article

References (67)

1. Akiyoshi J., Nishizono A., Yamada K., Nagayama H., Mifune K. and Fujii I. (1995) Rapid desensitization of serotonin 5-HT2C receptorstimulated intracellular calcium mobilization in CHO cells transfected with cloned human 5-HT2C receptors. J. Neurochem. 64, 2473-2479.
2. Amat J., Sparks P. D., Matus-Amat P., Griggs J., Watkins L. R. and Maier S. F. (2001) The role of the habenular complex in the elevation of dorsal raphe nucleus serotonin and the changes in the behavioral responses produced by uncontrollable stress. Brain Res. 917, 118-126.
3. De Angelis L. and File S. E. (1979) Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice. Psychopharmacology (Berl) 64, 127-129.
4. Ase A. R., Reader T. A., Hen R., Riad M. and Descarries L. (2000) Altered serotonin and dopamine metabolism in the CNS of serotonin 5-HT(1A) or 5-HT(1B) receptor knockout mice. J. Neurochem. 75, 2415-2426.
5. Bagdy G., Graf M., Anheuer Z. E., Modos E. A. and Kantor S. (2001) Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int. J. Neuropsychopharmacol. 4, 399-408.
6. Baumann M. H., Ayestas M. A., Dersch C. M. and Rothman R. B. (2001) 1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 24, 492-501.
7. Boadle-Biber M. C., Singh V. B., Corley K. C., Phan T. H. and Dilts R. P. (1993) Evidence that corticotropin-releasing factor within the extended amygdala mediates the activation of tryptophan hydroxylase produced by sound stress in the rat. Brain Res. 628, 105-114.
8. Boothman L., Raley J., Denk F., Hirani E. and Sharp T. (2006a) In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br. J. Pharmacol. 149, 861-869.
9. Boothman L. J., Mitchell S. N. and Sharp T. (2006b) Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis. Neuropharmacology 50, 726-732.
10. Bortolozzi A., Amargos-Bosch M., Adell A., Diaz-Mataix L., Serrats J., Pons S. and Artigas F. (2003) In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: Effect of antipsychotic drugs. Eur. J. Neurosci. 18, 1235-1246.
11. Bristow L. J., O'Connor D., Watts R., Duxon M. S. and Hutson P. H. (2000) Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100, 635, in the rat. Neuropharmacology 39, 1222-1236.
12. Charney D. S., Woods S. W., Goodman W. K. and Heninger G. R. (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 92, 14-24.
13. Christianson J. P., Ragole T., Amat J., Greenwood B. N., Strong P. V., Paul E. D., Fleshner M., Watkins L. R. and Maier S. F. (2010) 5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress. Biol. Psychiatry 67, 339-345.
14. Cremers T. I., Giorgetti M., Bosker F. J. et al. (2004) Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 29, 1782-1789.
15. Cremers T. I., Rea K., Bosker F. J., Wikstrom H. V., Hogg S., Mork A. And Westerink B. H. (2007) Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: Mechanistic studies. Neuropsychopharmacology 32, 1550-1557.
16. Ebner K., Singewald G. M., Whittle N., Ferraguti F. and Singewald N. (2008) Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology 33, 1929-1941.
17. Eriksson E., Engberg G., Bing O. and Nissbrandt H. (1999) Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20, 287-296.
18. File S. E., Zangrossi Jr H. and Andrews N. (1993) Social interaction and elevated plus-maze tests: Changes in release and uptake of 5-HT and GABA. Neuropharmacology 32, 217-221.
19. Fletcher P. J., Tampakeras M., Sinyard J., Slassi A., Isaac M. and Higgins G. A. (2009) Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice. Neuropharmacology 57, 259-267.
20. Gardier A. M., David D. J., Jego G. et al. (2003) Effects of chronic paroxetine treatment on dialysate serotonin in 5-HT1B receptor knockout mice. J. Neurochem. 86, 13-24.
21. Gavarini S., Becamel C., Altier C., Lory P., Poncet J., Wijnholds J., Bockaert J. and Marin P. (2006) Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability. Mol. Biol. Cell 17, 4619-4631.
22. Gehlert D. R., Shekhar A., Morin S. M., Hipskind P. A., Zink C., Gackenheimer S. L., Shaw J., Fitz S. D. and Sajdyk T. J. (2005) Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur. J. Pharmacol. 509, 145-153.
23. Gleason S. D. and Shannon H. E. (1998) Meta-chlorophenylpiperazine induced changes in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors in mice. Eur. J. Pharmacol. 341, 135-138.
24. Gobert A., Rivet J. M., Lejeune F., Newman-Tancredi A., Adhumeau- Auclair A., Nicolas J. P., Cistarelli L., Melon C. and Millan M. J. (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 36, 205-221.
25. Gommans J., Hijzen T. H., Maes R. A. and Olivier B. (1998) Discriminative stimulus properties of mCPP: Evidence for a 5-HT2C receptor mode of action. Psychopharmacology (Berl) 137, 292-302.
26. Graeff F. G. (2004) Serotonin, the periaqueductal gray and panic. Neurosci. Biobehav. Rev. 28, 239-259.
27. Graeff F. G., Guimaraes F. S., De Andrade T. G. and Deakin J. F. (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54, 129-141.
28. Hackler E. A., Turner G. H., Gresch P. J., Sengupta S., Deutch A. Y., Avison M. J., Gore J. C. and Sanders-Bush E. (2007) 5- Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3- carboxamide-induced anxiety-like behavior and limbic brain activation. J. Pharmacol. Exp. Ther. 320, 1023-1029.
29. Halberstadt A. L., van der Heijden I., Ruderman M. A., Risbrough V. B., Gingrich J. A., Geyer M. A. and Powell S. B. (2009) 5- HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 34, 1958-1967.
30. Hamon M., Fattaccini C. M., Adrien J., Gallissot M. C., Martin P. and Gozlan H. (1988) Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties. J. Pharmacol. Exp. Ther. 246, 745-752.
31. Heisler L. K., Pronchuk N., Nonogaki K. et al. (2007a) Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J. Neurosci. 27, 6956-6964.
32. Heisler L. K., Zhou L., Bajwa P., Hsu J. and Tecott L. H. (2007b) Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav. 6, 491-496.
33. Jorgensen H., Knigge U., Kjaer A., Vadsholt T. and Warberg J. (1998) Serotonergic involvement in stress-induced ACTH release. Brain Res. 811, 10-20.
34. Kayser V., Elfassi I. E., Aubel B., Melfort M., Julius D., Gingrich J. A., Hamon M. and Bourgoin S. (2007) Mechanical, thermal and formalin- induced nociception is differentially altered in 5-HT1A-/-, 5-HT1B-/-, 5-HT2A-/-, 5-HT3A-/- and 5-HTT-/- knock-out male mice. Pain 130, 235-248.
35. Keck M. E., Sartori S. B., Welt T., Muller M. B., Ohl F., Holsboer F., Landgraf R. and Singewald N. (2005) Differences in serotonergic neurotransmission between rats displaying high or low anxiety/ depression-like behaviour: Effects of chronic paroxetine treatment. J. Neurochem. 92, 1170-1179.
36. Kennedy A. J., Gibson E. L., O'Connell M. T. and Curzon G. (1993) Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology (Berl) 113, 262-268.
37. Kennett G. A., Whitton P., Shah K. and Curzon G. (1989) Anxiogeniclike effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur. J. Pharmacol. 164, 445-454.
38. Kennett G. A., Lightowler S., de Biasi V., Stevens N. C., Wood M. D., Tulloch I. F. and Blackburn T. P. (1994) Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33, 1581-1588.
39. Kennett G. A., Wood M. D., Bright F. et al. (1997) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36, 609-620.
40. Kennett G., Lightowler S., Trail B., Bright F. and Bromidge S. (2000) Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety. Eur. J. Pharmacol. 387, 197-204.
41. Liu R., Jolas T. and Aghajanian G. (2000) Serotonin 5-HT2 receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res. 873, 34-55.
42. Liu S., Bubar M. J., Lanfranco M. F., Hillman G. R. and Cunningham K. A. (2007) Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: Implications for understanding the neurobiology of addiction. Neuroscience 146, 1677-1688.
43. Lucki I., Ward H. R. and Frazer A. (1989) Effect of 1-(m-chlorophenyl) piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J. Pharmacol. Exp. Ther. 249, 155-164.
44. Maj J. and Moryl E. (1992) Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J. Neural Transm. Gen. Sect. 88, 143-156.
45. Maj J. and Moryl E. (1993) Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur. Neuropsychopharmacol. 3, 85-94.
46. Martin J. R., Bos M., Jenck F. et al. (1998) 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. 286, 913-924.
47. Martin C. B. P., Hamon M., Lanfumey L. and Mongeau R. (2010) The role of 5-HT2C receptors in the antidepressant response: A critical review, in Psychopathology and Pharmacotherapy of Depression: Recent Advances and Future Needs (Cryan J. F. and Leonard B. E., eds), Karger, Basel.
48. Meloni E. G., Reedy C. L., Cohen B. M. and Carlezon Jr W. A. (2008) Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: Correlation with anxiety-like behavior. Biol. Psychiatry 63, 832-839.
49. Millan M. J. (2005) Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. Therapie 60, 441-460.
50. Millan M. J. (2006) Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110, 135-370.
51. Millan M. J., Dekeyne A. and Gobert A. (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37, 953-955.
52. Mo B., Feng N., Renner K. and Forster G. (2008) Restraint stress increases serotonin release in the central nucleus of the amygdala via activation of corticotropin-releasing factor receptors. Brain Res. Bull. 76, 493-498.
53. Mongeau R., Blier P. and de Montigny C. (1997) The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments. Brain Res. Brain Res. Rev. 23, 145-195.
54. Ninan P. T. (2003) Obsessive-compulsive disorder: Implications of the efficacy of an SSRI, paroxetine. Psychopharmacol. Bull. 37(Suppl. 1), 89-96.
55. Papp M., Litwa E., Gruca P. and Mocaer E. (2006) Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol. 17, 9-18.
56. Pohl R., Yeragani V. K., Balon R. and Lycaki H. (1988) The jitteriness syndrome in panic disorder patients treated with antidepressants. J. Clin. Psychiatry 49, 100-104.
57. Queree P., Peters S. and Sharp T. (2009) Further pharmacological characterization of 5-HT(2C) receptor agonist-induced inhibition of 5-HT neuronal activity in the dorsal raphe nucleus in vivo. Br. J. Pharmacol. 158, 1477-1485.
58. Robinson E. S., Dalley J. W., Theobald D. E., Glennon J. C., Pezze M. A., Murphy E. R. and Robbins T. W. (2008) Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 33, 2398-2406.
59. Rodgers R. J., Boullier E., Chatzimichalaki P., Cooper G. D. and Shorten A. (2002) Contrasting phenotypes of C57BL/6JOlaHsd, 129S2/ SvHsd and 129/SvEv mice in two exploration-based tests of anxiety-related behaviour. Physiol. Behav. 77, 301-310.
60. Serrats J., Mengod G. and Cortes R. (2005) Expression of serotonin 5-HT2C receptors in GABAergic cells of the anterior raphe nuclei. J. Chem. Neuroanat. 29, 83-91.
61. Shah A. A. and Treit D. (2003) Excitotoxic lesions of the medial prefrontal cortex attenuate fear responses in the elevated-plus maze, social interaction and shock probe burying tests. Brain Res. 969, 183-194.
62. Sharp T., Boothman L., Raley J. and Queree P. (2007) Important messages in the 'post': Recent discoveries in 5-HT neurone feedback control. Trends Pharmacol. Sci. 28, 629-636.
63. Sills M. A., Lucki I. and Frazer A. (1985) Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP. Life Sci. 36, 2463-2469.
64. Thiebot M. H. (1986) Are serotonergic neurons involved in the control of anxiety and in the anxiolytic activity of benzodiazepines? Pharmacol. Biochem. Behav. 24, 1471-1477.
65. Trigo J. M., Renoir T., Lanfumey L., Hamon M., Lesch K. P., Robledo P. and Maldonado R. (2007) 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol. Psychiatry 62, 669-679.
66. Whitton P. and Curzon G. (1990) Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology (Berl) 100, 138-140.
67. Yamauchi M., Tatebayashi T., Nagase K., Kojima M. and Imanishi T. (2004) Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacol. Biochem. Behav. 78, 683-689.